Whitehawk Therapeutics Inc

WHWK

NASDAQ

Healthcare

Biotechnology

Pacific Palisades, CA, US40 employeesir.whitehawktx.com

$3.50

-0.04(-1.13%)

Mkt Cap $165M

$1.45

$4.08

52-Week Range

At a Glance

AI-generated

Whitehawk Therapeutics Inc reported a net loss of $20.6 million for FY 2025, a significant improvement from a $63.7 million net loss in FY 2024, primarily driven by an $87.3 million gain on the sale of its FYARRO business.

Revenue breakdown: Product (100%).

8-K

Whitehawk Therapeutics Inc filed an 8-K on March 12, 2026, under Item 2.02 announcing results of operations via Press Release in Exhibit 99.1. Item 2.02 and Item 9.01 are not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.

$165M

Market Cap

$5M

Revenue

-$14M

Net Income

Employees40

Fundamentals

How The Business Makes Money

Revenue by Segment

Product100%($33M)

Activity

What Changed Recently

Financial Results

Mar 11, 2026

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Ex

Peer Companies

Company	Price	Change	Market Cap	P/E
IMMXImmix Biopharma, Inc.	$8.91	+3.36%	$472M	-11.9
OVIDOvid Therapeutics Inc.	$2.19	+1.62%	$332M	-12.0
CNTXContext Therapeutics Inc.	$2.73	+3.02%	$251M	-10.9
MGNXMacroGenics, Inc.	$3.06	+5.69%	$195M	-2.5
ZNTLZentalis Pharmaceuticals,...	$2.63	+2.14%	$186M	-1.2
ONCYOncolytics Biotech Inc.	$0.96	+2.94%	$96M	-3.7
PLRXPliant Therapeutics, Inc.	$1.35	+2.65%	$84M	-0.5
CLNNClene Inc.	$5.19	+6.13%	$52M	-2.1

Analyst View

Company Profile

CIK0001422142

ISINUS00032Q1040

CUSIP00032Q104

Phone551 321 2234

Address17383 Sunset Blvd, Suite A250, Pacific Palisades, CA, 90272, US

SEC EDGAR